Table 2.
Baseline characteristics of the patients with TRG = 0, TRG > 0, and watch-and-wait group.
| TRG = 0 | TRG > 0 | Watch-and-wait | |
|---|---|---|---|
| Total, No. | 30 | 42 | 29 |
| Sex, No. (%) | |||
| Female | 13 (43.3) | 21 (50) | 5 (17.2) |
| Male | 17 (56.7) | 21 (50) | 24 (82.8) |
| Age, median (IQR) | 56 (47-59) | 56 (48-62) | 58 (52-64) |
| Clinical T stage, No. (%) | |||
| T2 | 3 (10) | 0 (0) | 10 (34.5) |
| T3 | 23 (76.7) | 38 (90.5) | 18 (62.1) |
| T4 | 4 (13.3) | 4 (9.5) | 1 (3.4) |
| Clinical N stage, No. (%) | |||
| N0 | 3 (10) | 0 (0) | 5 (17.2) |
| N1 | 15 (50) | 21 (50) | 12 (41.4) |
| N2 | 12 (40) | 21 (50) | 12 (41.4) |
| Baseline Tumor Max Length, median (IQR), cm | 4.8 (3.35-5.90) | 5.15 (4.03-5.95) | 4.7 (3.28-5.87) |
| Baseline CEA, median (IQR), ng/mL | 3.76 (1.08-6.17) | 4.21 (1.56-13.21) | 3.58 (1.12-6.03) |
TRG, tumor regression grade; IQR, interquartile range; CEA, carcinoembryonic antigen.